TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03539601
Drug: Crisaborole ointment, 2%
DrugBank: Crisaborole (DB05219)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Applied twice a day (BID)
Study: NCT03539601
Drug: Pimecrolimus cream, 1%
DrugBank: Pimecrolimus (DB00337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Applied BID
Study: NCT03539601
Drug: Crisaborole Vehicle
DrugBank: Crisaborole (DB05219)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Applied BID
Study: NCT00465088
Drug: atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg at bedtime
Study: NCT01067144
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1200 mg Gabapentin preoperative dose, 300 mg of Gabapentin 3-times a day postoperative doses for 72-hour post-surgical period.
Study: NCT01067144
Drug: Lorazepam (active control)
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mg Lorazepam (active control) given pre-operatively in a single dose.
Study: NCT00190632
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02672709
Drug: apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03278028
Drug: A-101 Vehicle Solution
Normalized name: Neisseria meningitidis serogroup A oligosaccharide diphtheria CRM197 protein conjugate vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NADA fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine / Neisseria meningitidis serogroup W-135 oligosaccharide diphtheria CRM197 protein conjugate vaccine / Neisseria meningitidis serogroup Y oligosaccharide diphtheria CRM197 protein conjugate vaccine Injection [Penmenvy]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A-101 Vehicle Solution
Study: NCT00973687
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01285466
Drug: BEZ235 + paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01285466
Drug: BKM120 + paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01285466
Drug: BEZ235 + paclitaxel + trastuzumab
Normalized name: Paclitaxel
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01285466
Drug: BKM120 + paclitaxel + trastuzumab
Normalized name: Paclitaxel
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00568321
Drug: RN624
Normalized name: Risankizumab
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 50 mcg/kg
Study: NCT00568321
Drug: RN624
Normalized name: Risankizumab
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mcg/kg
Study: NCT01008696
Drug: Rabeprazole
Normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rabeprazole 20 mg tablet orally once daily before breakfast for 28 to 56 days.
Study: NCT01008696
Drug: Lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole 30 mg capsule orally once daily before breakfast for 28 to 56 days.
Study: NCT03619538
Drug: Nefopam
Normalized name: nefopam
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The nefopam group received 120 mg nefopam (Acupan, Pharmbio, France) by continuous iv infusion over the study period (48h)
Study: NCT00003941
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003941
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003941
Drug: ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01020838
Drug: Florbetaben (BAY94-9172)
Normalized name: florbetaben
DrugBank: Florbetaben F-18 (DB09148)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous injection 1-5ml, 300 MBq (+/- 20%)
Study: NCT01167426
Drug: Glatiramer Acetate 20 mg/0.5 mL
DrugBank: Glatiramer (DB05259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/1.0 mL formulation of glatiramer acetate utilizing the autoject 2 for glass syringe.
Study: NCT01167426
Drug: Glatiramer acetate 20 mg/0.5 mL
DrugBank: Glatiramer (DB05259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/0.5 mL formulation of glatiramer acetate utilizing the autoject 2 20 mg/0.5 mL device.
Study: NCT01859078
Drug: Baricitinib
Normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally
Study: NCT00203424
Drug: Erlotinib + Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Erlotinib every day for 24 weeks and Bevacizumab every 3 weeks for a total of 8 doses
Study: NCT01427933
Drug: Eribulin
Normalized name: Eribulin
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered intravenously
Study: NCT00491127
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01859078
Drug: Digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00491127
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00491127
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00010283
Drug: beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02799095
Drug: ALKS 4230
Normalized name: ALKS 29
DrugBank: ALKS 29 (DB05723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion over 30 minutes given daily for 5 consecutive days followed by an off-treatment period
Study: NCT02799095
Drug: ALKS 4230 + pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion of ALKS 4230 over 30 minutes given daily for 5 consecutive days followed by an off-treatment period; pembrolizumab administered IV once with ALKS 4230 on the first day of each cycle
Study: NCT02095158
Drug: Oxymetazoline HCL Cream 1.0%
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxymetazoline HCL Cream 1.0% applied to the face once daily for 52 weeks.
Study: NCT00271258
Drug: SODIUM DIVALPROATE
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02366728
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide is a standard chemotherapy given to all enrolled patients at a targeted dose of 150-200mg/m2/d for 5 days every 5 (± 1) weeks for a total of 6 to 12 cycles at the discretion of the treating oncologist.
Study: NCT02366728
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.4mL of saline given in the opposite groin 1 day before the fourth vaccine in all groups
Study: NCT02366728
Drug: Basiliximab
Normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Group III will receive basiliximab infusions (20 mg I.V) 1 week before the first vaccine and 1 week before the second vaccine.
Study: NCT00274508
Drug: tiotropium bromide
Normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02003092
Drug: RX-5902
Normalized name: P-p68 inhibitor rx-5902
DrugBank: Supinoxin (DB19010)
Approvals — FDA: no, EMA: no, PMDA: no
Description: escalating doses (mg)
Study: NCT00832884
Drug: Lacosamide
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.7 mg/kg (up to maximum of 50 mg) x 5 subjects x 30 minutes; 1.4 mg/kg (up to a maximum of 100 mg) x 5 subjects x 30 minutes; 2.1 mg/kg (up to a maximum of 150 mg) x 5 subjects x 30 minutes; 2.9 mg/kg (up to a maximum of 200 mg) x 5 subjects x 30 minutes.~0.7 mg/kg (up to a maximum of 50 mg) x 5 subjects x 15 minutes; 1.4 mg/kg (up to a maximum of 100 mg) x 5 subjects x 15 minutes; 2.1 mg/kg (up to a maximum of 150 mg) x 5 subjects x 15 minutes; 2.9 mg/kg (up to a maximum of 200 mg) x 5 subjects x 15 minutes
Study: NCT04339829
Drug: Dacomitinib
Normalized name: DACOMITINIB
DrugBank: Dacomitinib (DB11963)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dacomitinib orally on a continuous daily basis at a starting dose of 45 mg QD
Study: NCT00555672
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5- fluorouracil is given as 4000 mg/m\^2 total dose over 96 hr continuous infusion of a 21 day chemotherapy cycle. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
Study: NCT00555672
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin is given 80 mg/m\^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
Study: NCT00555672
Drug: sunitinib malate
Normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: sunitinib is given orally 37.5mg /day for 14 days followed by 7 days of drug free period. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
Study: NCT00133861
Drug: Botulinum toxin
Normalized name: Botulinum toxin
DrugBank: Botulinum toxin type B (DB00042)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01053988
Drug: FF Inhalation Powder
Normalized name: FF-10101-01
DrugBank: FF-10101-01 (DB16050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Corticosteroid (ICS)
Study: NCT01397461
Drug: ozenoxacin placebo
DrugBank: Enoxacin (DB00467)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cream
Study: NCT01397461
Drug: retapamulin 1% ointment
DrugBank: Retapamulin (DB01256)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ointment
Study: NCT01397461
Drug: ozenoxacin 1% cream
Normalized name: OZENOXACIN 1% CREAM,TOP
DrugBank: Enoxacin (DB00467)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1% cream
Study: NCT03224104
Drug: TG02
Normalized name: Tigilanol tiglate
DrugBank: Tigilanol tiglate (DB18800)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The initial cohorts of Groups A and B will receive TG02 at 200 mg on intermittent schedules in combination with either RT or TMZ. TG02 will be escalated to 250 mg if the dose decision criteria are met in the first cohort.~The initial cohort in Group C will receive TG02 alone at 250 mg on intermittent schedules. It will be continued at this dose if feasible or decreased to 200 or 150 mg if not tolerated.
Study: NCT01124279
Drug: AMG 853
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose administration of AMG 853 in tablet form to healthy adult subjects
Study: NCT01223729
Drug: Acetyl-L-Carnitine
Normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g acetyl-L carnitine twice a day
Study: NCT03632772
Drug: Solifenacin 5Mg
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: We compared the safety and therapeutic efficacy between Solifenacin and Mirabegron in men with benign prostate hyperplasia and having overactive bladder symptoms immediately after Transurethral Resection of the Prostate.
Study: NCT03632772
Drug: Mirabegron 50 MG
Normalized name: mirabegron 50 MG
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: We compared the safety and therapeutic efficacy between Solifenacin and Mirabegron in men with benign prostate hyperplasia and having overactive bladder symptoms immediately after Transurethral Resection of the Prostate.
Study: NCT03224104
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: For group B TMZ will be given in the standard 28-day cycle regimen (150-200 mg/m2) for 5 days.
Study: NCT00227188
Drug: Pneumococcal 7-valent conjugate vaccine Prevnar
Normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03910712
Drug: Pyrotinib
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrotinib were administered 400 mg orally daily. Oral administration within 30 minutes after breakfast, and continuous administration for 21 days for 1 cycle.
Study: NCT03910712
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab were administered every 3 weeks intravenously (8 mg/kg loading doses followed by 6 mg/kg maintenance doses).
Study: NCT03058783
Drug: IDP-124 Vehicle Lotion
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDP-124 Vehicle Lotion, twice-daily application
Study: NCT00857142
Drug: Opana
Normalized name: Opana
DrugBank: Oxymorphone (DB01192)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02225600
Drug: 40 IU Intranasal Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 IU intranasal oxytocin
Study: NCT02225600
Drug: 24 IU intranasal Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02809573
Drug: Chidamide
Normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: In the lead-in period, patients take a single dose of Chidamide tablet on the first day and then off for 3 days before the first cycle begins. In the subsequent treatment cycles, Chidamide tablets are given orally on Day 1,4,8 and 11 of each cycle.
Study: NCT02129933
Drug: Bevacizumab-IRDye800CW
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous administration of a microdose (4.5mg, subtherapeutic) of Bevacizumab-IRDye800CW 2 days prior to the fluorescence endoscopy procedure.~\* amendment June 2015: topical administration bevacizumab-800CW (100ug/ml)
Study: NCT02809573
Drug: adriacin
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On Day 1, Adriacin is given in a 20-minute IV infusion at 50 mg/m\^2 soon after cyclophosphamide administration.
Study: NCT02809573
Drug: vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On Day 1, vincristine is given in IV infusion at 1.4 mg/m\^2 after adriacin administration.
Study: NCT02809573
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On Day 1 to 5, prednisone is given orally at 100 mg once a day
Study: NCT00525889
Drug: IL-2
Normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection at a dose of 4.5x10\^6 IU/day, three times weekly for 28 days starting on day 0.
Study: NCT00525889
Drug: Rapamycin
Normalized name: Rapamycin
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally, initial daily dose of 2mg. At day 7, dose adjusted to achieve and maintain whole blood trough levels of 5-10 ng/ml.
Study: NCT01479114
Drug: rh-GCSF
Normalized name: anti-D (rh) immunoglobulin
DrugBank: Human Rho(D) immune globulin (DB11597)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ug/kg/day intravenously for 3 days
Study: NCT01137955
Drug: Rifaximin
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin 400mg orally three times a day for 10 days total
Study: NCT02805049
Drug: Echinocandins
Normalized name: Echinocandin B, 1-((4R,5R)-4-hydroxy-N2-((4''-(pentyloxy)(1,1':4',1''-terphenyl)-4-yl)carbonyl)-5-(2-(trimethylammonio)ethoxy)-l-ornithine)-4-((4S)-4-hydroxy-4-(4-hydroxyphenyl)-l-allothreonine)-
DrugBank: Rezafungin (DB16310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients included in this protocol require routine treatment with caspofungin or micafungin. Though this intervention is under study, it is not modified by this protocol.
Study: NCT01418651
Drug: Savella
Normalized name: Savella
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: milnacipran 25 to 200 mg daily, divided into two doses (morning and evening)
Study: NCT04632589
Drug: Losartan Potassium
Normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: subjects ingest 50mg losartan potassium tablet daily for 6 weeks
Study: NCT01467700
Drug: Ramelteon SL
Normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramelteon SL tablets
Study: NCT00983320
Drug: quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: flexible dosage (50 to 300 mg)
Study: NCT06628544
Drug: Metformin is administered on the day 0
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin is administered on the day 0
Study: NCT06628544
Drug: Metformin is administered on the day 9
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin is administered on the day 9
Study: NCT06628544
Drug: Metformin is administered on the day 85
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin is administered on the day 85
Study: NCT01502228
Drug: 150-Water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be imaged immediately before, and between 14-28 days after initiation of Sunitinib therapy, in the single bed position using the Siemens Biograph 64 TruePoint system located in the clinical facilities of the I.U. Cancer Center. Administer 15O-water at 50 mCi/dose, IV.
Study: NCT01502228
Drug: 62Cu-ethylglyoxal bis
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imaging with 62Cu-ETS will be done immediately following imaging with 150-water. Patients will be imaged immediately before, and between 14-28 days after, initiation of Sunitinib therapy using the Siemens Biograph 64 TruePoint system located in the clinical facilities of the I.U. Cancer Center. Administer 62Cu-ETS in the range of 20-25 mCi/Dose, IV.
Study: NCT01502228
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04322617
Drug: Anlotinib plus the same Immune Checkpoint Inhibitors.
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib, 8mg po qd, D1-D14 every 21days.
Study: NCT04322617
Drug: Anlotinib plus the new Immune Checkpoint Inhibitors.
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib, 8mg po qd, D1-D14 every 21days.
Study: NCT04322617
Drug: Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib, 8mg po qd, D1-D14 every 21days.
Study: NCT03334409
Drug: Pazopanib Hydrochloride
Normalized name: Pazopanib Hydrochloride
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT01353625
Drug: CC-115
Normalized name: CC-115
DrugBank: CC-115 (DB12740)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A (actively recruiting): Dose level starts with 0.5mg daily by mouth in cycles of 28 days. Level increases for different patient cohorts in 100% or 50% increments until optimal dose schedule is established for further study. Treatment continues for as long as patient benefits (i.e., until disease progression or unacceptable toxicity).~Part B: Optimal dose schedule is administered in 28-day cycles until disease progression.
Study: NCT01821378
Drug: Lurasidone
Normalized name: Lurasidone
DrugBank: Lurasidone (DB08815)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lurasidone 20 mg once daily
Study: NCT01821378
Drug: Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2
Normalized name: lurasidone hydrochloride 80 MG
DrugBank: Lurasidone (DB08815)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lurasidone 80 mg once daily
Study: NCT01317901
Drug: TRU-016
Normalized name: Immunoglobulin, anti-(human cd antigen cd37) (synthetic human-mus musculus fragment tru-016), dimer
DrugBank: Otlertuzumab (DB16275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg TRU-016 lyophilized solution for infusion at 10 or 20 mg/kg (or 6 mg/kg, if necessary) on Days 1 and 15 of each 28 day cycle
Study: NCT01317901
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bendamustine by IV administration on Days 1 and 2 of each 28 day cycle.
Study: NCT01250951
Drug: Deferasirox
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01317901
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab by IV administration at 375 mg/m\^2 on Day 2 of each 28 day cycle.
Study: NCT01415401
Drug: Brinzolamide 1% / timolol 0.5% maleate fixed combination
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01514201
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT01514201
Drug: Veliparib
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01377662
Drug: OND-PR002 and MPh-IR
Normalized name: orchard grass pollen extract
DrugBank: Dactylis glomerata pollen (DB10379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: OND-PR002~Single daily oral doses of 8 mg Ond-PR002~Drug: MPh-IR~Single daily oral doses of 20 mg MPh-IR
Study: NCT03593759
Drug: Prednisone or Prednisolone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone/prednisolone tablet